Comparing Pre- and Postoperative Etoricoxib Administration Versus Only Postoperative on Third Molar Extraction Sequelae and Oral Health Quality of Life: a Prospective Quasi-Experimental Study

Objectives This study aimed to compare the impact of pre- and postoperative etoricoxib administration versus only postoperative on third molar extraction sequelae and oral health quality of life. Materials and methods This prospective quasi experimental study involved 56 patients, divided into a study group receiving preemptive etoricoxib 120 mg before surgery and postoperative etoricoxib 120 mg ( n = 28), and a control group receiving preemptive placebo before surgery and postoperative etoricoxib 120 mg ( n = 28). Follow-up assessments were conducted at 3- and 7-days post-surgery, recording swelling, trismus, and adverse events. Patients rated perceived pain using the visual analog scale (VAS) and completed an oral health-related quality of life (OHRQoL) questionnaire at specified intervals. Statistical analysis employed non-parametric tests (i.e., the Mann–Whitney test, Friedman test, and Wilcoxon sign test) with P < 0.05. Results Significantly lower VAS scores were reported in the study group throughout the follow-up period ( P < 0.05). Pharmacological protocol did not have a significant impact on postoperative edema and trismus ( P > 0.05). However, double etoricoxib intake significantly improved postoperative quality of life on day 3 after surgery ( P < 0.05). Conclusions Pre- and postoperative etoricoxib 120 mg intake in third molar surgery reduced postoperative pain and enhanced postoperative quality of life on day 3 after surgery. Importantly, it was equally effective in managing swelling and trismus compared to exclusive postoperative intake. Clinical Relevance Preemptive etoricoxib use may decrease patient discomfort following impacted mandibular third molar extraction.